InvestorsHub Logo
Followers 32
Posts 1683
Boards Moderated 0
Alias Born 01/11/2014

Re: Inoviorulez post# 26807

Tuesday, 07/16/2019 6:31:24 AM

Tuesday, July 16, 2019 6:31:24 AM

Post# of 34625
Pembrolizumab was approved based on ph1 study results... so if PC results are compelling, an accelerated approval is not out of question..


https://www.ascopost.com/issues/october-15-2014/first-approval-of-pd-1-inhibitor-pembrolizumab-in-unresectable-or-metastatic-melanoma/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News